Startup profile · funding coverage
Tiny Health funding, valuation and investors
Microbiome testing and intelligence platform with at-home gut and vaginal health products; raised $33M Series B led by B Capital in September 2026.
Verified company research · funding, investors and latest developments
Keep track of Tiny Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$33M · September 29, 2026
Latest known valuation
Undisclosed
Series B · September 29, 2026
Total disclosed equity funding
$33M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b
Investors in latest funding
Lead: B Capital
Other: Alumni Ventures , Black Opal Ventures , Denver Ventures , Pave Health Ventures , Gaingels , Pari Passu Ventures , Spero Ventures , TheVentureCity , Overwater Ventures
Overview
Tiny Health offers microbiome testing and data interpretation for consumers and healthcare practitioners. Founder Cheryl Sew Hoy announced a $33M Series B on September 29, 2026 led by B Capital, bringing total reported funding to $46M.
New investors included Alumni Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Gaingels and Pari Passu Ventures, with existing backers Spero Ventures, TheVentureCity and Overwater Ventures. The company claimed nearly 200,000 customers and more than 6,000 healthcare practitioners reached; these company metrics are not independently audited or clinical-outcome measurements. Tiny Health's specific AV check and valuation were not disclosed.
Why Tiny Health is interesting
Tiny Health markets microbiome insights across consumer and provider channels, moving beyond infant gut testing to adult and reproductive health. Its growth must be assessed separately from clinical evidence that microbiome test results improve specific health outcomes.
Product & use cases
At-home microbiome sample collection and data reports for gut and vaginal microbiomes, combined with practitioner education and the Powered by Tiny partner platform.
- Consumer gut and vaginal microbiome testing
- Provider-enabled microbiome insights and longitudinal research
- Research tools and partnerships using microbiome data
Key facts
- September 29, 2026: $33M Series B led by B Capital; total reported funding $46M.
- Alumni Ventures specifically named as a new Series B investor.
- Company reported nearly 200,000 customers and over 6,000 practitioners served.
Funding history (newest first)
Series B
2026-09-29 $33M Valuation: Undisclosed- B Capital (lead)
- Alumni Ventures (participant)
- Black Opal Ventures (participant)
- Denver Ventures (participant)
- Pave Health Ventures (participant)
- Gaingels (participant)
- Pari Passu Ventures (participant)
- Spero Ventures (participant)
- TheVentureCity (participant)
- Overwater Ventures (participant)
Source: Read source · tinyhealth.com
Investors in our directory
Funds linked from Tiny Health's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Its distinctive vertical starting with maternal/infant health and growing practitioner channel could support distribution, although the clinical utility of individual microbiome readings varies by condition and remains an evidence question.
The main diligence issues are the clinical usefulness of recommendations, repeat testing, provider retention, customer acquisition economics and the distinction between tests sold and improved clinical outcomes.
-
Viome direct
Consumer microbiome and personalized health testing.
-
ZOE adjacent
Nutrition and metabolic-health personalization with microbiome inputs.
-
Evvy adjacent
Vaginal microbiome testing and treatment support; overlaps only part of Tiny Health's product.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Tiny Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.